The clinical performance is complex and often involves multiple systemic burdens. Early identification and standardization of the diagnosis is essential for improving the prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspections, laboratory tests and pathological evaluation.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat genetic metabolic disorders have been significantly improved. Treatment needs to closely monitor efficacy and adverse reactions, adapting timely to changes in the course of the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of delayed transmission of carcinogenicity. The platform serves a team of internationally recognized experts in the field of genetic metabolism in China, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.